A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease-Reference-Cited by-同舟云学术

A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease

Published:2002-02 Issue:2 Volume:122 Page:512-530
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Sandborn William J.,Feagan Brian G.,Hanauer Stephen B.,Lochs Herbert,Löfberg Robert,Modigliani Robert,Present Daniel H.,Rutgeerts Paul,Schölmerich Jurgen,Stange Eduard F.,Sutherland Lloyd R.

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference115 articles.

1. Approaches to evaluating evidence;Kitching,1998

2. Low dose steroids and clinical relapse in Crohn's disease: a controlled trial;Smith;Gut,1978

3. Postoperative treatment with corticosteroids and salazosulphapyridine (Salazopyrin) after radical resection for Crohn's disease;Bergman;Scand J Gastroenterol,1976

4. The clinical effect of salazosulphapyridine (Salazopyrin r) in Crohn's disease. A controlled double-blind study;Anthonisen;Scand J Gastroenterol,1974

5. Sulphasalazine in asymptomatic Crohn's disease. A multicentre trial;Lennard-Jones;Gut,1977

Cited by 589 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Qualitative and Psychometric Evaluation of 29-Item Patient-Reported Outcomes Measurement Information System® to Assess General Health-Related Quality of Life in Patients With Moderately to Severely Active Inflammatory Bowel Disease;Value in Health;2024-09

2. The changes of serum uric acid and total cholesterol are associated with the severity of Crohn's disease：A cross-sectional study;2024-08-17

3. Management of Crohn’s disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023;Intestinal Research;2024-07-31

4. Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease;New England Journal of Medicine;2024-07-18

5. Real-life treatment persistence and treatment outcomes of Finnish patients with inflammatory bowel disease receiving vedolizumab as first-line biological treatment;Heliyon;2024-06